Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Kent Hutchison to Double-Blind Method

This is a "connection" page, showing publications Kent Hutchison has written about Double-Blind Method.

 
Connection Strength
 
 
 
0.592
 
  1. Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, Hutchison KE. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology (Berl). 2017 Dec; 234(23-24):3417-3429.
    View in: PubMed
    Score: 0.101
  2. Littlewood RA, Claus ED, Arenella P, Bogenschutz M, Karoly H, Ewing SW, Bryan AD, Hutchison KE. Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology (Berl). 2015 Apr; 232(7):1261-8.
    View in: PubMed
    Score: 0.083
  3. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007 Sep; 64(9):1069-77.
    View in: PubMed
    Score: 0.050
  4. Ray LA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, Hutchison KE. Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology (Berl). 2007 Sep; 193(4):449-56.
    View in: PubMed
    Score: 0.049
  5. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun; 31(6):1310-7.
    View in: PubMed
    Score: 0.046
  6. Hutchison KE, Rutter MC, Niaura R, Swift RM, Pickworth WB, Sobik L. Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology (Berl). 2004 Oct; 175(4):407-13.
    View in: PubMed
    Score: 0.041
  7. Bidwell LC, Martin-Willett R, Melendez SN, Rosa L, Giordano G, Hutchison KE, Bryan AD. LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder. PLoS One. 2024; 19(9):e0308262.
    View in: PubMed
    Score: 0.041
  8. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003 Oct; 28(10):1882-8.
    View in: PubMed
    Score: 0.038
  9. Lim AC, Ghahremani DG, Grodin EN, Green R, Bujarski S, Hartwell EE, Courtney KE, Hutchison K, Miotto K, Ray LA. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. Drug Alcohol Depend. 2019 07 01; 200:181-190.
    View in: PubMed
    Score: 0.028
  10. Hutchison KE, Swift R. Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans. Psychopharmacology (Berl). 1999 Apr; 143(4):394-400.
    View in: PubMed
    Score: 0.028
  11. Ray LA, Green R, Roche DJO, Bujarski S, Hartwell EE, Lim AC, Rohrbaugh T, Ghahremani D, Hutchison K, Miotto K. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. Alcohol Clin Exp Res. 2018 Mar; 42(3):613-623.
    View in: PubMed
    Score: 0.026
  12. Ray LA, Hutchison KE, Ashenhurst JR, Morrow AL. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. Alcohol Clin Exp Res. 2010 Aug; 34(8):1479-87.
    View in: PubMed
    Score: 0.015
  13. Ray LA, Hutchison KE, MacKillop J, Miranda R, Audette A, Swift R, Monti PM. Effects of naltrexone during the descending limb of the blood alcohol curve. Am J Addict. 2008 Jul-Aug; 17(4):257-64.
    View in: PubMed
    Score: 0.013
  14. Rohsenow DJ, Tidey JW, Miranda R, McGeary JE, Swift RM, Hutchison KE, Sirota AD, Monti PM. Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. Exp Clin Psychopharmacol. 2008 Jun; 16(3):215-22.
    View in: PubMed
    Score: 0.013
  15. David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec; 5(6):935-42.
    View in: PubMed
    Score: 0.010
  16. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999 Aug; 23(8):1386-94.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)